- IRS Information-Reporting Thresholds Could Cut Filing Burden for Millions
- Ireland Extends Living City Initiative Tax Relief for Property Refurbishment
- U.S. Countervailing Duty on Russian Phosphate Fertilizers Finalized at 12.71%
- India Gold and Silver Import Authorisation Ends Customs Hold on Bullion
- EU Vape Customs Operation Exposes Cross-Border Excise and Customs Threats
- United States Trade Tariffs: Businesses Prepare for CAPE Refund Filings
- World Bank Capital Increase 2026: Final Maturity Reached for IBRD/IFC
- 99.7% Accurate: The Brazil VAT Split-Payment 2026 Audit is In
North America
The $600 rule is dead. The IRS 1099-K Threshold 2026 is now officially $2,000, bringing a permanent end to the digital payment reporting controversy.
The IRS just clarified OBBBA Depreciable Property lives for high-tech manufacturing. From 3-year silicon tools to 5-year green tech, the tax savings are massive.
Paper checks are gone, but scammers are here. The new mandate for digital-only payments has triggered a massive wave of IRS Electronic Refund Scams.
Cash transfers just got more expensive. The new OBBBA Remittance Excise Tax imposes a 1% levy on cash and money order remittances sent abroad.
The service industry just got a raise. The IRS has finalized the OBBBA No Tax on Tips rules, exempting gratuities from federal income tax while adding strict anti-abuse guardrails.
The numbers are in, and they aren’t pretty. 2026 Taxpayer Sentiment shows that most Americans feel the tax system is unfair and too expensive as the IRS deadline looms.
Generational wealth starts now. The IRS confirms that 4 million children have been signed up for OBBBA Trump Accounts since January.
Trade just got digital. The new Mexico Agro-Compliance Certificate is now mandatory for agricultural exporters seeking VAT zero-rating in Mexico.
Innovation just got a tax break. The IRS has officially restored immediate Section 174 R&D Expensing for domestic costs, while tightening rules on foreign research.
Trade enforcement hits the medicine cabinet. The Section 232 Pharma Tariffs are now live, introducing a 100% duty on foreign-made APIs to force domestic manufacturing.

